EMAIL THIS PAGE TO A FRIEND

Pharmaceutical research

Osteotropic polypeptide nanoparticles with dual hydroxyapatite binding properties and controlled cisplatin delivery.


PMID 25504453

Abstract

Nanoparticles with prolonged residence time in bone constitute a valuable strategy for bone disease treatments. The aim of this work was to synthesise a simple nanoparticulate system exhibiting both anticancer and hydroxyapatite binding properties for potential bone cancer applications. The amphiphilic copolymer poly(γ-benzyl-glutamate)-block-poly(glutamic acid) (PBLG-b-PGlu) was synthetised by ring opening polymerization and nanoparticles were obtained by a simple nanoprecipitation method. Nanoparticles were characterized in terms of cisplatin interaction, association, and release as well as interaction with hydroxyapatite and their cytoxicity was studied in three prostate cancer cell lines. PBLG-b-PGlu nanoparticles of ~50 nm in size were successfully prepared. They could display for the first time dual hydroxyapatite binding and anticancer properties mediated by the PGlu moiety. They could complex cisplatin at a drug loading content of 6.2% (w/w). Cisplatin release was triggered by physiological concentrations of chloride ions according to an almost zero order kinetics during 14 days. Simultaneously, these nanoparticles showed in vitro hydroxyapatite binding. Finally, they were shown to exert a cytotoxic effect in three prostate cancer cell lines that potentially metastasize to bone. These properties suggest the potential utility of cisplatin-loaded PBLG-b-PGlu nanoparticles as carrier systems for the treatment of bone metastases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

74440
(−)-Nopol, purum, ≥98.0% (sum of enantiomers, GC)
C11H18O
W503401
2,4-Dimethylthiazole, ≥95%, FG
C5H7NS
02487
Chloroform, analytical standard
CHCl3
PHR1552
Chloroform, Pharmaceutical Secondary Standard; Certified Reference Material
CHCl3
151858
Chloroform-d, "100%", 99.96 atom % D
CCl3D
494275
Chloroform-d, "100%", 99.96 atom % D, contains 0.03 % (v/v) TMS
CCl3D
431915
Chloroform-d, "100%", 99.96 atom % D, contains 0.5 wt. % silver wire as stabilizer
CCl3D
151823
Chloroform-d, 99.8 atom % D
CCl3D
225789
Chloroform-d, 99.8 atom % D, contains 0.03 % (v/v) TMS
CCl3D
612200
Chloroform-d, 99.8 atom % D, contains 0.05 % (v/v) TMS
CCl3D
434876
Chloroform-d, 99.8 atom % D, contains 0.1 % (v/v) TMS
CCl3D
151831
Chloroform-d, 99.8 atom % D, contains 1 % (v/v) TMS
CCl3D
416754
Chloroform-d, ≥99.8 atom % D, contains 0.5 wt. % silver foil as stabilizer
CCl3D
530735
Chloroform-d, ≥99.8 atom % D, contains 0.5 wt. % silver foil as stabilizer, 0.03 % (v/v) TMS
CCl3D
570699
Chloroform-d, ≥99.8 atom % D, anhydrous
CCl3D
C2210000
Cisplatin, European Pharmacopoeia (EP) Reference Standard
H6Cl2N2Pt
Y0001018
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
H6Cl2N2Pt
156914
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
453323
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
424005
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
417939
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
417920
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 1 % (v/v) TMS
C2D6OS
570672
Dimethyl sulfoxide-d6, anhydrous, 99.9 atom % D
C2D6OS
569585
Dimethyl sulfoxide-d6, 99.9 atom % D, anhydrous
C2D6OS
151874
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
522058
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
612324
Dimethyl sulfoxide-d6, "Special HOH", ≥99.9 atom % D
C2D6OS
716731
Dimethyl sulfoxide-d6, "Special HOH", ≥99.9 atom % D
C2D6OS
296147
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
574341
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS